CAR T-Cell therapy sends multiple myeloma into lasting remission
In an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy — chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. …read more
